Ovarian ablation for premenopausal early-stage breast cancer: An update

Luigi Celio, Emilio Bajetta, Luisa Toffolatti, Laura Catena, Elena Beretta, Roberto Buzzoni

Research output: Contribution to journalArticlepeer-review


Ovarian ablation is the oldest form of systemic treatment of breast cancer and consists of removal of the main source of estrogen biosynthesis in premenopausal women. Over the last century several different means of stopping ovarian function have been studied: surgical oophorectomy, ovarian irradiation, and more recently, chemical castration by gonadotropin-releasing hormone analog therapy. In unselected patients the response rate to ovarian ablation is of about 35% but the likelihood of response is considerably higher for patients with hormonal receptor-positive tumors, the therapy being most effective in women who are actively menstruating. In spite of this evidence, the role of ovarian ablation in the management of early-stage breast cancer still remains controversial. Here we review current evidence supporting the value of this ablative procedure as an adjuvant and update ongoing clinical research to refine our knowledge about its use.

Original languageEnglish
Pages (from-to)191-194
Number of pages4
Issue number3
Publication statusPublished - May 2000


  • Adjuvant therapy
  • Early breast cancer
  • Ovarian ablation
  • Premenopausal women

ASJC Scopus subject areas

  • Cancer Research


Dive into the research topics of 'Ovarian ablation for premenopausal early-stage breast cancer: An update'. Together they form a unique fingerprint.

Cite this